US 12,453,766 B2
RSV RNA vaccines
Giuseppe Ciaramella, Sudbury, MA (US); Kapil Bahl, Medford, MA (US); Amy Espeseth, Chalfont, PA (US); Andrew J. Bett, Lansdale, PA (US); Pedro Cejas, Oreland, PA (US); Lan Zhang, Chalfont, PA (US); and Christine Shaw, Reading, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, Inc., Cambridge, MA (US)
Filed on Jan. 19, 2024, as Appl. No. 18/418,127.
Application 18/418,127 is a continuation of application No. 16/965,589, granted, now 11,911,453, previously published as PCT/US2019/015412, filed on Jan. 28, 2019.
Claims priority of provisional application 62/623,240, filed on Jan. 29, 2018.
Prior Publication US 2024/0299525 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/0019 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding a prefusion respiratory syncytial virus (RSV) F protein, wherein the ORF encodes an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 5, wherein identity defines the percentage of amino acid residues in the RSV F protein that are identical to residues of SEQ ID NO: 5 after introducing any necessary gaps to align the two full-length sequences.